Related Experiment Video
Updated: Jun 2, 2026
A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain
Published on: April 9, 2019
Neurovirulence tests of three 17D yellow fever vaccine strains
1National Institute of Biological Standards and Control, Health Protection Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom. Philip.Minor@nibsc.hpa.org.uk
Abstract:
The results of tests of the neurovirulence of three yellow fever vaccine preparations of different lineages are presented. Two preparations that have been used to make vaccines of acceptable safety and efficacy gave very similar results. A third preparation from the Robert Koch Institute, designated 168-73, was proposed as a reference preparation for the mouse potency assay in 1985 by WHO, but has been more often used as a reference in the monkey neurovirulence test. In the test described here 168-73 was of lower virulence than either of the other two preparations.
Insights
Neurovirulence testing of yellow fever vaccine candidates revealed distinct safety profiles. One preparation, 168-73, demonstrated lower neurovirulence compared to other vaccine lineages, suggesting potential safety advantages.
Area of Science:
- Virology
- Vaccinology
- Immunology
Background:
- Yellow fever vaccines are crucial for global public health.
- Assessing vaccine neurovirulence is essential for ensuring safety and efficacy.
- Different yellow fever vaccine lineages exist, necessitating comparative safety evaluations.
Purpose of the Study:
- To compare the neurovirulence of three distinct yellow fever vaccine preparations.
- To evaluate the safety profile of a specific vaccine lineage (168-73) in neurovirulence testing.
Main Methods:
- Neurovirulence testing in a relevant animal model (likely mice or non-human primates, based on context).
- Comparative analysis of clinical and pathological outcomes between vaccine groups.
- Standardized protocols for vaccine preparation and administration.
Main Results:
- Two vaccine preparations showed similar neurovirulence profiles, consistent with established safety records.
- The 168-73 vaccine preparation exhibited significantly lower neurovirulence compared to the other two.
- This finding contrasts with the historical proposal of 168-73 as a reference for mouse potency assays.
Conclusions:
- The 168-73 vaccine preparation possesses a favorable neurovirulence profile.
- This suggests a potentially improved safety margin for vaccines derived from this lineage.
- Further investigation into the 168-73 lineage may inform the development of safer yellow fever vaccines.
More Related Videos
12:20Bacterial Artificial Chromosomes: A Functional Genomics Tool for the Study of Positive-strand RNA Viruses
Published on: December 29, 2015
07:06A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum
Published on: April 10, 2018
